OBJECTIVE. Several clinical studies have shown the efficacy of 177Lu-labeled prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) for metastatic castration-resistant prostate cancer (mCRPC). The purpose of this article is to present results of a systematic review and meta-analysis aimed at compiling and outlining efficacy and safety data on 177Lu-PSMA RLT for mCRPC across all studies published to date. CONCLUSION. The results of the systematic review and meta-analysis suggest that 177Lu-PSMA RLT is an effective treatment of advanced-stage mCRPC that is refractory to standard therapeutic options and that it has a low toxicity profile. High-level evidence from randomized control trials is crucial for confirming the effectiveness of 177Lu-PSMA RLT and for instituting this therapy in the routine clinical care of patients with mCRPC.
Keywords: Lu-PSMA; castration-resistant prostate cancer; efficacy; lutetium-177; metastasis; prostate-specific membrane antigen; radioligand therapy; safety.